Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics
YMAB Price/Volume Stats
| Current price | $14.71 | 52-week high | $20.90 |
| Prev. close | $14.84 | 52-week low | $4.60 |
| Day low | $14.36 | Volume | 189,796 |
| Day high | $15.13 | Avg. volume | 399,172 |
| 50-day MA | $15.73 | Dividend yield | N/A |
| 200-day MA | $9.01 | Market Cap | 643.96M |
YMAB Stock Price Chart Interactive Chart >
Y-mAbs Therapeutics, Inc. (YMAB) Company Bio
Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.
Latest YMAB News From Around the Web
Below are the latest news stories about Y-MABS THERAPEUTICS INC that investors may wish to consider to help them evaluate YMAB as an investment opportunity.
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology IndexNEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced it will be added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective prior to the market open on Monday, December 18, 2023. The NASDAQ Biotechnology Index is designed to track the performance of |
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics IncY-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)Y-mAbs Therapeutics Inc (NASDAQ:YMAB), a commercial-stage biopharmaceutical company, has recently witnessed a significant insider purchase that has caught the attention of investors and market analysts alike. |
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call TranscriptY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning and welcome to Y-mAbs Therapeutics Third Quarter 2023 Earnings Conference Call. Please note that today’s event is being recorded. At this time, all participants are in a listen-only mode. Instructions for the question-and-answer session will follow after the prepared remarks. […] |
Q3 2023 Y-mAbs Therapeutics Inc Earnings CallQ3 2023 Y-mAbs Therapeutics Inc Earnings Call |
YMAB Price Returns
| 1-mo | -10.85% |
| 3-mo | 30.52% |
| 6-mo | 173.93% |
| 1-year | 158.98% |
| 3-year | -47.67% |
| 5-year | -37.35% |
| YTD | 115.69% |
| 2023 | 39.75% |
| 2022 | -69.90% |
| 2021 | -67.26% |
| 2020 | 58.43% |
| 2019 | 53.64% |
Loading social stream, please wait...